This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kasitanon, N Articles by Petri, M Search for Related Content PubMed PubMed Citation Articles by Kasitanon, N Articles by Petri, M Social Bookmarking                         What's this?

Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis

Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, USA

D M Fine

Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, USA

M Haas

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, USA

L S Magder

Department of Epidemiology and Preventive Medicine, University of Maryland, Baltimore, USA

M Petri

Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, USA, mpetri{at}jhmi.edu

The objective of this study was to identify clinical predictors of response to initial mycophenolate mofetil (MMF) therapy for membranous lupus nephritis (MLN). We observed the clinical outcomes of patients in the Hopkins Lupus Cohort within the first year of initiation of treatment with MMF therapy for newly diagnosed MLN, classified according to the new International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification. Complete renal remission was defined as proteinuria less than 500 mg/24 hours. Demographic, clinical, treatment and laboratory data were examined for their association with renal remission. Twenty-nine MLN patients treated with MMF were identified. Eleven (38%) patients achieved complete renal remission by 12 months. Of those taking hydroxychloroquine, 7/11 (64%) were in remission within 12 months compared to only 4/18 (22%) of those not on hyroxychloroquine (P 0.036 based on a log-rank test). This association persisted after controlling for the presence of anti-ds-DNA (P 0.026). Our results provide evidence that hydroxychloroquine has a benefit for renal remission when MMF is used as the initial therapy for MLN. Although hydroxychloroquine is frequently stopped in patients with lupus nephritis, this study suggests it should be started or maintained.

Key Words: hydroxychloroquine • membranous lupus nephritis • mycophenolate mofetil

Lupus, Vol. 15, No. 6, 366-370 (2006)
DOI: 10.1191/0961203306lu2313oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G Ruiz-Irastorza, M Ramos-Casals, P Brito-Zeron, and M A Khamashta Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review Ann Rheum Dis, January 1, 2010; 69(01): 20 - 28. [Abstract] [Full Text] [PDF]

				C Nannini, C. Crowson, E. Matteson, and K. Moder Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study Lupus, April 1, 2009; 18(5): 394 - 399. [Abstract] [PDF]

				S Masood, D Jayne, and Y Karim Beyond immunosuppression - challenges in the clinical management of lupus nephritis Lupus, February 1, 2009; 18(2): 106 - 115. [Abstract] [PDF]

				R M Andrade, G S Alarcon, L A Gonzalez, M Fernandez, M Apte, L M Vila, G McGwin Jr, J D Reveille, and for the LUMINA Study Group Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV) Ann Rheum Dis, June 1, 2008; 67(6): 829 - 834. [Abstract] [Full Text] [PDF]

				G Ruiz-Irastorza and M. Khamashta Hydroxychloroquine: the cornerstone of lupus therapy Lupus, April 1, 2008; 17(4): 271 - 273. [PDF]

				A Siso, M Ramos-Casals, A Bove, P Brito-Zeron, N Soria, S Munoz, A Testi, J Plaza, J Sentis, and A Coca Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival Lupus, April 1, 2008; 17(4): 281 - 288. [Abstract] [PDF]

				G. S Alarcon, G. McGwin, A. M Bertoli, B. J Fessler, J. Calvo-Alen, H. M Bastian, L. M Vila, J. D Reveille, and for the LUMINA Study Group Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) Ann Rheum Dis, September 1, 2007; 66(9): 1168 - 1172. [Abstract] [Full Text] [PDF]

				P. M. Stassen, C. G. M. Kallenberg, and C. A. Stegeman Use of mycophenolic acid in non-transplant renal diseases Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1013 - 1019. [Full Text] [PDF]